Together with poloxamer 407 as adjuvant the recombinant type I (rCPB) cysteine proteinase of Leishmania major was screened as a potential vaccines against L. major in a mouse model. Using the footpad thickness increase to monitor the clinical outcome/cutaneous lesion at site of L. major delivery, it was possible to document that rCPB allowed BALB/c mice to mount a partial protective response (Rafati et al., 2002).
